PNC Financial Services Group
MNPR icon

PNC Financial Services Group’s Monopar Therapeutics MNPR Stock Holding History

PNC Financial Services Group’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$558 Buy
7
+1
+17% +$107 ﹤0.01% 5127
2026
Q2 		$556 Buy
+6
New +$371 ﹤0.01% 4961

Other funds holding MNPR

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Quadrature Capital
Quadrature Capital London, United Kingdom $16.1B AUM 61.25% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

PNC Financial Services Group's MNPR Position: Q3 2026 in Review

PNC Financial Services Group increased its Monopar Therapeutics (MNPR) stake by 17% in Q3 2026, buying an estimated $107 and bringing the position to 7 shares worth $558. The position accounts for ﹤0.01% of the portfolio, ranked #5127.

PNC Financial Services Group first reported a position in MNPR in Q2 2026 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

  • PNC Financial Services Group held 7 shares of Monopar Therapeutics worth $558 as of Q3 2026.
  • PNC Financial Services Group bought 1 Monopar Therapeutics share in Q3 2026, an estimated $107.
  • Monopar Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #5127 holding.
  • PNC Financial Services Group first reported a position in Monopar Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.